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RESULTS RESULTS
Retrospective review of ticagrelor and clopidogrel in adult patients in 
the setting of dual antiplatelet therapy after percutaneous coronary 
intervention in a community hospital
Jessica Hernandez, Pharm.D., Laura Neubauer, Pharm.D., Heidi Clarke, Pharm.D., BCCCP, Radhan B. Gopalani, Pharm.D., BCPS, Marcus E. St. John, M.D., FACC, FSCAI
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL
• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is 
standard of care after percutaneous coronary intervention (PCI)1,2,4. 
• Ticagrelor is a newer/more potent P2Y12 inhibitor that is preferred 
over clopidogrel due to its enhanced pharmacokinetic properties 
and superior clinical outcomes3,5. This agent is limited, however, by 
its high cost, increased risk of bleeding and BID dosing.
• Between 2008-2016, patient non-adherence nearly tripled when 
ticagrelor and prasugrel gained FDA approval and their use began to 
increase6. 
• De-escalation of P2Y12 inhibitor therapy (transitioning from a more 
potent agent to a less potent one, i.e. ticagrelor  clopidogrel) is a 
strategy that provides patients with the more effective therapy 
when risk of restenosis is at its highest, while mitigating the risk of 
non-adherence secondary to cost and BID dosing in the long term. 
• De-escalation can be classified according to when it occurs relative 
to initiation of P2Y12 inhibitor therapy: 
• An expert consensus published in 2017 outlines how this switch 
should occur, including the recommendation to administer the first 
dose of clopidogrel 24 hours after ticagrelor is discontinued, 
regardless of when de-escalation occurs. Based on bleed risk, a 
clopidogrel dose of 75 mg or a 300-600 mg loading dose is 
recommended7.
The purpose of this project is to retrospectively review the use of 
ticagrelor and clopidogrel in adult patients following stent placement 
and to observe the incidence of de-escalation over a 6 month period at 
Baptist Hospital of Miami.  
• Single-center, retrospective chart review of patients receiving DAPT 
after PCI at Baptist Hospital between January 1st 2019 and June 30th
2019
• Inclusion Criteria:
• Patients  ≥ 18 years of age 
• Received aspirin plus ticagrelor or clopidogrel
• Exclusion Criteria:
• P2Y12 inhibitor prior to admission
• Contraindications to the use of a P2Y12 inhibitor 
• Aspirin allergy
• Pregnancy
• Primary Outcomes:
• # of patients receiving ticagrelor or clopidogrel 
• # of patients who were de-escalated from ticagrelor to 
clopidogrel
All authors of this presentation have nothing to disclose concerning possible financial or 
personal relationships with commercial entities that may have direct or indirect interest 
in the subject matter of this presentation.
This was an observational project that was designed to evaluate prescribers’ preference 
in P2Y12 inhibitor therapy for the initiation of DAPT after PCI. The results indicate that 
ticagrelor was the preferred P2Y12 inhibitor in the majority of cases, with only a small 
fraction being de-escalated to clopidogrel.
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Baseline Demographics (N=164) 
Mean age, years (range) 64 (35 – 91)
Gender – male, n (%) 108 (65.9)
STEMI, n (%) 67 (40.6)
NSTEMI, n (%) 97 (59.4)
Concomitant aspirin use 164 (100)
n= 13
102
(85%)
18 
(15%)
De-Escalation of P2Y12 Inhibitor Therapy
No Yes
• 73% of patients were started on ticagrelor for DAPT after PCI
• Of the 44 patients who received clopidogrel, 77% were treated for 
NSTEMI
• Of the 120 patients who received ticagrelor, 18 patients were de-escalated to 
clopidogrel
• Most common reasons for de-escalation were bleed risk and lack of insurance 
• 15% of patients started on ticagrelor were de-escalated to clopidogrel
• 50% were de-escalated with a 300 mg loading dose 
• 39% were de-escalated with a 75 mg dose 
• 11% were de-escalated with a 600 mg loading dose 
• The average time from the last dose of ticagrelor to the first dose of clopidogrel in 
patients who were de-escalated was ~11 hrs 
• Small sample size
• Unable to justify the reason for selected clopidogrel dose for de-escalation
• Only patients de-escalated during the acute/early phase were captured in the 
analysis, as data regarding de-escalation on discharge is unknown 
De-escalation of P2Y12 Inhibitor Therapy
# of patients de-escalated 18/120
Clopidogrel dose given at time of de-escalation:
• 75 mg
• 300 mg 
• 600 mg 
7/18
9/18
2/18
Avg time (hours) between last dose of ticagrelor and first dose of
clopidogrel (range) 11:01 (01:59 – 19:11)
Acute 
(< 24 h)
Early  
(1d <30 d) 
Late 
(30d  1 yr)
Very late  
(> 1 yr) 44
(27%)
120
(73%)
Number of Patients Receiving 
Ticagrelor vs Clopidogrel 
Clopidogrel Ticagrelor
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